Cantor Fitzgerald Analyzes Axsome Therapeutics,’s FY2024 Earnings
November 11, 2023
🌥️Trending News
Cantor Fitzgerald recently issued an analysis of Axsome Therapeutics ($NASDAQ:AXSM), Inc.’s FY2024 earnings. Axsome Therapeutics, Inc. is a clinical-stage biopharmaceutical company that develops innovative therapies for the management of central nervous system (CNS) disorders. Their goal is to become the leading company in the development of novel treatments for these disorders, with an emphasis on major depressive disorder, Alzheimer’s disease, and other forms of dementia. The company’s FY2024 earnings are expected to be a key factor in the company’s future success as they move towards a larger presence in the CNS space. Cantor Fitzgerald believes that the earnings will bring significant growth to Axsome Therapeutics, Inc. as they continue to develop and commercialize their products.
They also believe that the company has the potential to become a major player in the CNS space and that their FY2024 earnings will provide a good indication of their progress. Cantor Fitzgerald is optimistic about Axsome Therapeutics, Inc.’s future, and believes that their FY2024 earnings will be a good measure of the company’s potential for growth and success. With the right strategies in place and continued development of their products, the company could become a major player in the CNS space.
Earnings
According to their report, as of June 30 2021, Axsome Therapeutics lost 0.0M USD in total revenue and 32.28M USD in net income. This marks a 100.0% decrease in total revenue compared to the previous year. However, in the last 3 years, Axsome Therapeutics’s total revenue has grown from 0.0M USD to 46.7M USD. This indicates that the company may experience significant growth in the near future.
About the Company
Income Snapshot
Below shows the total revenue, net income and net margin for Axsome Therapeutics. More…
| Total Revenues | Net Income | Net Margin |
| 182.49 | -184.45 | -95.6% |
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Axsome Therapeutics. More…
| Operations | Investing | Financing |
| -111.49 | -0.45 | 475.66 |
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Axsome Therapeutics. More…
| Total Assets | Total Liabilities | Book Value Per Share |
| 611.64 | 332.83 | 2.52 |
Key Ratios Snapshot
Some of the financial key ratios for Axsome Therapeutics are shown below. More…
| 3Y Rev Growth | 3Y Operating Profit Growth | Operating Margin |
| 0.0% | – | -95.2% |
| FCF Margin | ROE | ROA |
| -61.3% | -55.6% | -17.8% |
Market Price
On Friday, the stock opened at $59.6 and closed at $57.4, a decrease of 4.4% from its prior closing price of 60.1. This signifies a downtrend in the stock price, which indicates that investors are not fully confident in the company’s earnings report. It is uncertain if this trend will continue in the near future or if Axsome Therapeutics will be able to rebound. Live Quote…
Analysis
At GoodWhale we’ve been analyzing AXSOME THERAPEUTICS‘s financials, and the results have been interesting. According to our Star Chart, AXSOME THERAPEUTICS is strong in terms of asset and growth, yet weak in dividend and profitability. Based on this information, we’ve classified AXSOME THERAPEUTICS as a ‘cheetah’ type of company – one that has achieved high revenue or earnings growth but is considered less stable due to lower profitability. Investors who may be interested in such a company include those who like the idea of high revenue or earnings growth and yet are aware of the risks associated with investment in an unstable company. However, AXSOME THERAPEUTICS has a low health score of 3/10 with regard to its cashflows and debt, which means it is less likely to sustain future operations in times of crisis. Therefore, potential investors should assess their risk tolerance before investing. More…
Peers
The company’s lead product candidate, AXS-05, is in Phase III clinical development for treatment-resistant depression (TRD), and has completed Phase II clinical development for Alzheimer’s disease (AD) agitation. Provention Bio Inc, NGM Biopharmaceuticals Inc, Orphazyme AS are all companies focused on developing novel therapies for CNS disorders and are AXS-05’s main competitors in the market.
– Provention Bio Inc ($NASDAQ:PRVB)
Prevention Bio Inc is a clinical-stage biopharmaceutical company developing novel, best-in-class therapeutics for life-threatening infectious diseases with high unmet medical need. The company’s primary focus is on developing its lead product candidate, PB01, for the prevention and treatment of severe sepsis. PB01 is a first-in-class monoclonal antibody that targets a key protein involved in the body’s inflammatory response to infection. Prevention Bio is currently enrolling patients in a Phase 2 clinical trial of PB01 in patients with severe sepsis.
Prevention Bio’s market cap of $643.47 million and ROE of -80.87% reflect the company’s high potential and significant risk. Prevention Bio is a clinical-stage company, meaning its products are still in development and have not yet been approved for market. While the company’s lead product candidate, PB01, has shown promise in early clinical trials, it remains to be seen whether it will be safe and effective in larger trials and ultimately be approved for market. Given the significant risks associated with clinical-stage companies, investors are likely to require a higher return on their investment in Prevention Bio than in more established companies.
– NGM Biopharmaceuticals Inc ($NASDAQ:NGM)
NGM Biopharmaceuticals Inc is a clinical stage biopharmaceutical company. The company focuses on the discovery and development of novel therapeutic proteins for the treatment of serious diseases. NGM Biopharmaceuticals Inc has a market cap of 438.05M as of 2022, a Return on Equity of -28.16%. The company’s main products are in the areas of oncology, diabetes and obesity.
– Orphazyme AS ($OTCPK:OZYMF)
Orphazyme AS is a pharmaceutical company that focuses on the development of treatments for rare diseases. The company has a market cap of 5.56M as of 2022 and a Return on Equity of -845.21%. The company’s focus on rare diseases gives it a niche market, which allows it to charge higher prices for its products. However, the company’s high prices may limit its customer base and its ability to grow its business.
Summary
Axsome Therapeutics, Inc. recently reported their FY2024 earnings which were met with a negative response from the market. On the day of the announcement, the stock price dropped significantly. This could be attributed to investors feeling disappointed with the results, or concerned by the overall outlook for the company. Analysis of the financials showed that revenues decreased by a significant amount while costs increased. This led to a decrease in operating income and lower profit margins.
Additionally, analysts noted that cash flow was negative in the quarter, indicating that the company may have difficulty meeting its debt obligations in the future. Overall, this seems to be a concerning situation for investors and may require closer examination in order to make an informed decision.
Related Posts
Recent Posts
Investing Everyone Can Do.
Investing shouldn’t be exclusive to a select few. We believe everyone should have the opportunity to grow their wealth. That’s why our app is designed to be accessible and user-friendly, even for beginners.
